key: cord-0872290-tjqh33hm authors: Cousyn, L.; Sellem, B.; Palich, R.; Bendetowicz, D.; Agher, R.; Delorme, C.; Tubiana, R.; Valantin, M-A.; Seang, S.; Schneider, L.; Fayçal, A.; Dudoit, Y.; Abdi, B.; Ndoadoumgue, A.; Assoumou, L.; Katlama, C. title: Olfactory and gustatory dysfunctions in COVID-19 outpatients: a prospective cohort study date: 2021-03-22 journal: Infect Dis Now DOI: 10.1016/j.idnow.2021.03.004 sha: 9ce2fc3327f354e578f000f95defc33f108b81d2 doc_id: 872290 cord_uid: tjqh33hm Objectives: To describe the characteristics, evolution and risk factors for long-term persistence of olfactory and gustatory dysfunctions (OGD) in COVID-19 outpatients. Patients and methods: We conducted a prospective study in SARS-CoV-2 infected outpatients with OGD. Weekly phone interviews were set up starting from COVID-19 onset symptoms and over the course of 60 days, using standardized questionnaires that included a detailed description of general symptoms and OGD. The primary outcome was the proportion of patients with complete recovery of OGD at D30. Rate and time to recovery of OGD, as well as risk factors for late recovery (>30 days), were evaluated using Cox regression models. Results: Ninety-eight outpatients were included. The median time to onset of OGD after first COVID-19 symptoms was 2 days (IQR 0-4). The 30-day recovery rate from OGD was 67.5% (95%CI 57.1-75.4) and the estimated median time of OGD recovery was 20 days (95%CI 13-26). Risk factors for late recovery of OGD were a complete loss of smell or taste at diagnosis (HR=0.26, 95%CI 0.12-0.56, p=0.0005) and age over 40 years (HR=0.56, 95%CI 0.36-0.89, p=0.01). Conclusions: COVID-19 patients with complete loss of smell or taste and over age 40 are more likely to develop persistent OGD and should rapidly receive sensorial rehabilitation. Olfactory impairment following an upper respiratory tract infection is common and up to 40% of cases of anosmia in adults have been related to post-viral olfactory dysfunction [1] . Acute olfactory and gustatory dysfunctions (OGD) appear to be even more prevalent in mild-tomoderate COVID-19 patients (40 to 80%) [2] [3] [4] [5] , whereas these symptoms have rarely been reported in hospitalized patients (about 5%) [6] . As some patients experience long-term manifestations of COVID-19 [7] including OGD [8, 9] , a better knowledge of the temporal dynamics and risk factors potentially associated with persistent symptoms would be useful for more appropriate patient management. Although prospective studies have been conducted, such factors have not yet been reported. However, the monitoring of patients was not sufficiently close and OGDs were at times subject to selfassessùent, which may have been less sensitive than a clinician's evaluation [8, 9] . Herein, we conducted the COVID-19 Infection and Related ANOsmia and ageusia (CIRANO) prospective study -with a systematic weekly teleconsultation -in order to describe the characteristics and evolution of OGD over time and to investigate the factors associated with persistent OGD. The The main study outcome was the proportion of individuals with OGD recovery at D30. The secondary outcomes were median time to OGD recovery, the proportion of individuals with OGD recovery at D60, and risk factors for persistent OGD after D30. The evaluated risk factors included age, gender, cycle threshold (Ct) value of SARS-CoV-2 RT-PCR (as a proxy for nasopharyngeal viral load), intensity of OGD (partial or complete loss), and number of olfactory and gustatory symptoms at diagnosis. Data were summarized using the following descriptive statistics: non-missing sample size, median, and interquartile range (IQR) for continuous variables. The frequency and percentages (based on the non-missing sample size) of observed levels were reported for categorical variables. The rate and time to OGD recovery and analyses of factors associated with OGD recovery were evaluated using Cox regression models, accounting for staggered entries in the study. Models included age (≤ or > 40 years), gender, RT-PCR Ct values, intensity of OGD, and number of olfactory or gustatory symptoms at diagnosis. We also plotted the Kaplan-Meier curves for OGD recovery. The research was conducted according to the recommendations outlined in the Helsinki declaration. This study was approved by an institutional review board (CPP Ile-de-France X, Paris, France, N°47-2020). In the COVID-PSL cohort, 300 patients (69.9%) experienced OGD, of whom 98 were enrolled in the CIRANO study. Two patients were lost to follow-up after day 21 and day 30; no participant was hospitalized, required oxygen therapy or died. SARS-CoV2 diagnosis was based on positive RT-PCR tests (n=96) or positive SARS-CoV-2 antibody tests (n=2). All of the descriptive characteristics are reported in OGDs were present in 17% and 10% of patients respectively (Figure 1 ). The multivariable analysis highlighted two factors independently associated with the persistence of OGD ( were not associated with the persistence of symptoms. Our study highlights the evolution of smell and taste disorders over the course of COVID-19. Olfactory and gustatory symptoms usually appear early -during the first 2-3 days -and last less than 30 days in two-thirds of cases. In addition, GD disappears more rapidly than OD. We also identified predictors of late recovery: complete loss of smell and taste at diagnosis and age over 40 years were associated with longer duration of OGD. To our knowledge, this is the first longitudinal cohort to highlight risk factors for persistent OGD symptoms [8, 9] . The pathophysiological mechanisms leading to anosmia in the context of viral infections remain unclear but may be based on the neurotropic characteristics of SARS-CoV-2 [10] . Indeed, SARS-CoV-2 can bind to the angiotensin-converting enzyme 2 (ACE2) receptor and thereby enter human cells such as neurons [11] . In addition, the ability of SARS-CoV-1 (close to SARS-CoV-2) to invade the olfactory bulb, and consequently the central nervous system, have been highlighted in transgenic mice [12] . As a result, anosmia and ageusia in COVID-19 are very likely to be caused by the involvement of the olfactory and gustatory nervous systems [13, 14] . Before the COVID-19 pandemic, post-viral anosmia had been investigated for other viruses [15] . In most cases, however, patients had associated congestion and obstruction, which were sufficient to explain the anosmia. In our study, only 49% of patients had symptoms of rhinitis, and direct infection of olfactory receptor neurons caused by SARS-CoV-2 could also be involved [16] . One reported argument against this hypothesis was that OGD recovery J o u r n a l P r e -p r o o f necessitated less than a week, whereas the replacement of neurons would take 8 to 10 days, with 5 additional days for cilia maturation [16, 17] . However, our study and others highlighted a higher median recovery time than previously reported [8, 9] . In our experience, the rapid onset of OGD within two days, as well as the long recovery time would suggest a direct viral mechanism. Our cohort was primarily composed of young female healthcare workers. During the first wave of COVID-19 in France, healthcare workers -who are known to be predominantly femalehad greater access to SARS-CoV-2 PCR. That said, other studies have also reported a predominance of women (from 63 to 77%) experiencing OGD in a COVID-19 context [2, 8, 18] . Whether genetic differences could be responsible for differing OGD prevalence between women and men remains to be determined. Similarly, as OGD appears to be less frequent in Asian than in European populations, it has been hypothesized that genetic differences in SARS-CoV-2 entry receptors could explain the discrepancy [19] . Our study has several limits. First, because of the lockdown and recommended isolation for COVID-19 patients, we were not able to physically examine patients. However, its bears mentioning that OGDs are subjective symptoms that could to some extent rely on the patient's perception. Since the end of the lockdown, objective measurements using psychophysical olfactory tests have indeed been performed [20] . Second, our data focused only on outpatients with mild-to-moderate disease. Although prevalence of OGD seems lower in hospitalized patients with a more severe disease, our results cannot be extrapolated to them. Therefore, new investigations would be interesting, in particular to analyze the correlation between severity of the disease and duration of symptoms. Third, our patients were monitored for only two months. Extended aftercare could determine whether patients may have permanent aftereffects. Finally, Ct values for SARS-CoV-2 PCR, a proxy for viral quantification, were available for only 74 patients (76%). The statistical power in our study may consequently have been too low to detect any association between Ct values and OGD recovery, as previously described in the literature [21] . Besides, as PCR tests may have been performed a few days after the onset of symptoms, the peak of viral load may have been missed. Several therapies such as zinc, intranasal corticoid injections and systemic steroids have been used in post-viral OD, but have never proven to be effective [22] . To date, the only approved treatment is daily and long-term olfactory rehabilitation, which could improve the olfactory capacities of patients up to 30% [23] . However, whether olfactory rehabilitation could be effective in COVID-19 patients with anosmia still remains to be demonstrated. In summary, OGD in COVID-19 usually appear in the first days of illness and last less than 30 days. Patients with complete loss of smell or taste and over age 40 are more likely to develop long-term persistent sensory symptoms and should rapidly receive sensorial rehabilitation. Further studies are required to investigate new therapeutic approaches concerning COVID-19-related OGD. Cousyn: conceptualization, methodology, validation, investigation, data curation, writing -original draft, visualization, supervision Sellem: conceptualization, methodology, validation, investigation, data curation, writing -original draft, visualization, supervision Palich: conceptualization, investigation, writing -review & editing Bendetowicz: conceptualization, investigation, writing -review & editing Agher: software, formal analysis, resources, data curation, writing -review & editing conceptualization, investigation, writing -review & editing Tubiana: conceptualization, investigation, writing -review & editing Valantin: conceptualization, investigation, writing -review & editing Seang: conceptualization, investigation, writing -review & editing conceptualization, investigation, writing -review & editing Fayçal: conceptualization, investigation, writing -review & editing Dudoit: conceptualization, investigation, writing -review & editing Abdi: resources, writing -review & editing Ndoadoumgue: software, formal analysis, resources, data curation, writing -review & editing Assoumou: software, formal analysis, resources, data curation, writing -review & editing conceptualization, methodology, validation, investigation, writing -original draft, visualization, supervision Olfactory disorders following upper respiratory tract infections Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis: Otolaryngology-Head and Neck Surgery Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19 Prevalence and Recovery From Olfactory and Gustatory Dysfunctions in Covid-19 Infection: A Prospective Multicenter Study Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and prospective study Smell and taste dysfunction in patients with COVID-19 Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2 Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms MRI Evaluation of the Olfactory Clefts in Patients with SARS-CoV-2 Infection Revealed an Unexpected Mechanism for Olfactory Function Loss Prognosis of postviral olfactory loss: follow-up study for longer than one year Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection A lifetime of neurogenesis in the olfactory system Features of anosmia in COVID-19 Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients COVID-19 Viral Load in the Severity of and Recovery From Olfactory and Gustatory Dysfunction Treatment of post-viral olfactory dysfunction: an evidence-based review with recommendations Effects of olfactory training in patients with olfactory loss %) 15/95 (15.8) Gustatory disorders Delay between onset of the first COVID-19 symptoms and gustatory disorders, median %) 11/67 (16.4) Consequences of olfactory and gustatory disorders Anorexia, No. (%) 62 (63.3) Psychological impact, No. (%) 45 (45.9) Associated symptoms No associated symptoms %) 20 (20.4) Nausea and/or vomiting %) 12 (12.2) Chills, No. (%) 12 (12.2) Abdominal pain We thank our collaborators of the COVIDOM-19 PSL research group (F. Adda, C. Blanc, E.